Abstract
Objective: An increasing number of targeted therapies have been approved by the FDA for gynecologic malignancies. The expanded availability of affordable next-generation sequencing has allowed for widespread tumor testing for pathogenic mutations. We sought to describe the most frequent genetic mutations associated with common histologic subtypes of a selected cohort of ovarian and endometrial cancer patients at a single large academic medical center.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
